Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
Conditions with excess LIPIDS in the blood.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
A condition of elevated levels of TRIGLYCERIDES in the blood.
Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol.
Triglycerides are the most common type of fat in the body, stored in fat cells and used as energy; they are measured in blood tests to assess heart disease risk, with high levels often resulting from dietary habits, obesity, physical inactivity, smoking, and alcohol consumption.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed)
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Behaviors associated with the ingesting of alcoholic beverages, including social drinking.
An alcoholic beverage usually made from malted cereal grain (as barley), flavored with hops, and brewed by slow fermentation.
Drinkable liquids containing ETHANOL.
Fermented juice of fresh grapes or of other fruit or plant products used as a beverage.
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES.
A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)

Obesity, abdominal obesity, and clustering of cardiovascular risk factors in South Korea. (1/1436)

The aim of this study was first, to investigate the prevalence of obesity, abdominal obesity, and clustering of cardiovascular (CVD) risk factors, and secondly, to identify the BMI or waist circumference (WC) level at which clustering increases in South Koreans. A population-based, cross-sectional National Health Examination Survey was carried out in 1998. A total of 8,816 subjects (4,029 men and 4,787 women) aged 15-79 y were selected by stratified multistage probability sampling design. The measurements taken of the subjects included: height, weight, waist and hip circumference, blood pressure, fasting glucose, and lipids. The prevalence of BMI > or = 25 kg/m2 was 25.3% for men and 28.3% for women. The prevalence of WC >90 cm in men, and >80 cm in women was 18.5%, and 38.5%, respectively. Clustering of 3 or more CVD risk factors was 22.7% in men ad 21.7% in women. Using <21 kg/m2; as a referent, subjects with BMI of 23 kg/m2; and 27 kg/m2; had an odds ratio of 3.5 and 10.2 in men, and 3.1 and 6.7 in women, respectively for clustering of CVD risk factors. Using <65 cm as a referent, subjects with a WC of > or = 90 cm in men and > or = 85 cm in women had an odds ratio of 13.4, and 13.6, respectively for clustering of CVD risk factors. Considering the significant associations between clustering of CVD risk factors and BMI or WC, the present study suggests that high prevalence of overweight may have important implications for the health care system, even at a lower level of BMI or WC.  (+info)

Impact of obesity on lipid profiles in middle-aged women. (2/1436)

OBJECTIVE: The goal of the study was to analyze the impact of overweight on lipid and apolipoprotein A-I and B (apoA-I, apoB) profiles in the women's blood serum. MATERIAL AND METHODS: Seventy-five women without any symptoms of coronary heart disease were examined. Women were divided into two groups: those with normal weight and the body mass index (BMI) less than 25 (n=34, BMI 22.3+/-1.5; mean age 62+/-8.7 years) and overweight women (n=41, BMI 29.7+/-3.7; mean age 59+/-9.4). Weight and height were measured and blood serum concentrations of total cholesterol, high-density lipoprotein cholesterol, and triglycerides were determined after an overnight fasting. In the same serum samples the levels of apoA-I and B were measured using monoclonal antibodies against apo (Spinreact AA, Sant Esteve De Bas, Spain) by the immunoturbidimetry method. The serum samples were kept frozen at -40 degrees C until used. RESULTS: Total cholesterol and triglycerides levels were similar in the healthy and the overweight women groups (6.49+/-1.25 vs 6.52+/-1.18 mmol/l; p>0.05 and 1.21+/-0.71 vs 1.41+/-0.98 mmol/l; p>0.05, respectively). The concentrations of high-density lipoprotein cholesterol and apoA-I were significantly higher in the normal weight women compared to the overweight women (1.84+/-0.52 vs 1.40+/-0.29 mmol/l, p<0.001 and 1.40+/-0.26 vs 1.24+/-0.23 g/l, p<0.01, respectively). The level of apoB was significantly higher in the overweight female group compared to normal weight women (0.83+/-0.21 vs 0.74+/-0.18 g/l, p=0.049). The apoB/A-I ratio was significantly lower in the normal weight group than in the overweight group (0.055+/-0.15 vs 0.70+/-0.22; p<0.001). Moderate to strong correlations between apoA-I and high-density lipoprotein cholesterol concentrations were found in both groups (r=0.41, p<0.01 in the control female group and r=0.59, p<0.0001 in the overweight group, respectively). A similar level of correlation between apoB and total cholesterol was established in both groups (r=0.54, p<0.0005 and r=0.67, p<0.0001, respectively). CONCLUSION: Obesity in middle-aged women is associated with a significant decrease in serum high-density lipoprotein cholesterol and apoA-I levels, a significant increase in apoB and apoB/A-I ratio, even if serum total cholesterol and triglycerides concentrations are unaltered. Changes of the lipid profile in obese women are indicative of a higher risk of coronary heart disease.  (+info)

Another emerging event occurring during HIV infection treated with any antiretroviral therapy: frequency and role of gynecomastia. (3/1436)

To identify HIV-associated episodes of gynecomastia occurred during antiretroviral therapy in a cohort of around 1,000 patients, and to investigate potential correlations with demographic and epidemiological variables, clinical-laboratory markers of HIV disease, metabolic disturbances, and antiretroviral treatment, a cross-sectional survey of 1.007 patients treated for at least 12 months (669 males: 66.4%), identified all subjects with true (ultrasonography-confirmed) gynecomastia, after exclusion of all other predisposing conditions. Special attention was paid to eventual metabolic alterations, including lipodystrophy syndrome, dyslipidemia, and hyperglycemia, and administered antiretrovirals. Fifteen of the 516 evaluable male subjects (2.9%), developed gynecomastia when aged 12-58 years. A concurrent lipodystrophy was present in all cases, while hypertriglyceridemia, hypercholesterolemia, and hyperglycemia were found in 11, 6, and 3 patients, respectively. Duration of seropositivity and time from start of antiretroviral therapy varied significantly, and no correlation was found with HIV disease progression, but 5 patients never received protease inhibitors, while an efavirenz-based treatment apparently prompted gynecomastia in 4 protease inhibitor-naive patients, and worsened this sign in other 4 patients switching from a protease inhibitor-based HAART. One patient developed gynecomastia while on isolated nucleoside analogue therapy. In the whole patient group, stavudine proved the nucleoside analogue administered more frequently and for a more prolonged time. During the follow-up, no significant ameliorament of gynecomastia was observed despite eventual therapeutic changes. Gynecomastia, as an emerging untoward event of treated HIV infection, deserves further investigation, from an epidemiological, clinical, and especially pathogenetic point of view. The frequent association with metabolic abnormalities suggests some common ethiologic pathway with other HAART-related disturbances.  (+info)

Web-based targeted nutrition counselling and social support for patients at increased cardiovascular risk in general practice: randomized controlled trial. (4/1436)

BACKGROUND: Using the Internet may prove useful in providing nutrition counselling and social support for patients with chronic diseases. OBJECTIVE: We evaluated the impact of Web-based nutrition counselling and social support on social support measures, anthropometry, blood pressure, and serum cholesterol in patients at increased cardiovascular risk. METHODS: We conducted a randomized controlled trial among patients with increased cardiovascular risk in Canadian family practices. During 8 months, patients in the intervention group and control groups received usual care. Patients in the intervention group also had access to a Web-based nutrition counselling and social support tool (Heartweb). Site use during the study was monitored. We measured social support, body mass index, waist/hip ratio, blood pressure, and cholesterol levels at baseline and at 4 and 8 months to assess the effectiveness of the intervention. RESULTS: We randomized 146 patients into the Web-based intervention (n=73) or the control group (n=73). Within the Web-based intervention group, Heartweb was used by only 33% (24/73) of patients, with users being significantly younger than nonusers (P=.03). There were no statistically significant differences between the intervention group and the control group in changes in social support, anthropometry, blood pressure, and serum cholesterol levels. CONCLUSIONS: Uptake of the Web-based intervention was low. This study showed no favourable effects of a Web-based nutrition counselling and social support intervention on social support, anthropometry, blood pressure, and serum cholesterol. Improvements in reach and frequency of site use are needed to increase the effectiveness of Web-based interventions.  (+info)

Rare variant of apolipoprotein E (Arg136 -->Ser) in two normolipidemic individuals. (5/1436)

Through the analysis of the common apolipoprotein (apo) E gene polymorphism in large Caucasian population study with the PCR and subsequent restriction analysis, we have identified carriers of mutant allele Arg136-->Ser. Both of them (71-years-old female and her 43-years-old son) have normal lipid parameters. We suggest that Arg136-->Ser mutation in apoE is not necessarily connected with elevated lipid levels in all cases. Furthermore, so far unidentified factors (environmental and/or genetic) are important for the development of lipid metabolism disorders in apoE Arg136-->Ser mutation carriers.  (+info)

Dynamic genetic architecture of metabolic syndrome attributes in the rat. (6/1436)

The polydactylous rat strain (PD/Cub) is a highly inbred (F > 90) genetic model of metabolic syndrome. The aim of this study was to analyze the genetic architecture of the metabolic derangements found in the PD/Cub strain and to assess its dynamics in time and in response to diet and medication. We derived a PD/Cub x BN/Cub (Brown Norway) F2 intercross population of 149 male rats and performed metabolic profiling and genotyping and multiple levels of genetic linkage and statistical analyses at five different stages of ontogenesis and after high-sucrose diet feeding and dexamethasone administration challenges. The interval mapping analysis of 83 metabolic and morphometric traits revealed over 50 regions genomewide with significant or suggestive linkage to one or more of the traits in the segregating PD/Cub x BN/Cub population. The multiple interval mapping showed that, in addition to "single" quantitative train loci, there are more than 30 pairs of loci across the whole genome significantly influencing the variation of particular traits in an epistatic fashion. This study represents the first whole genome analysis of metabolic syndrome in the PD/Cub model and reveals several new loci previously not connected to the genetics of insulin resistance and dyslipidemia. In addition, it attempts to present the concept of "dynamic genetic architecture" of metabolic syndrome attributes, evidenced by shifts in the genetic determination of syndrome features during ontogenesis and during adaptation to the dietary and pharmacological influences.  (+info)

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. (7/1436)

OBJECTIVE: Pharmacological inhibition of the cholesteryl ester transfer protein (CETP) in humans increases high-density lipoprotein (HDL) cholesterol (HDL-C) levels; however, its effects on apolipoprotein A-I (apoA-I) containing HDL subspecies, apoA-I turnover, and markers of reverse cholesterol transport are unknown. The present study was designed to address these issues. METHODS AND RESULTS: Nineteen subjects, 9 of whom were taking 20 mg of atorvastatin for hypercholesterolemia, received placebo for 4 weeks, followed by the CETP inhibitor torcetrapib (120 mg QD) for 4 weeks. In 6 subjects from the nonatorvastatin cohort, the everyday regimen was followed by a 4-week period of torcetrapib (120 mg BID). At the end of each phase, subjects underwent a primed-constant infusion of (5,5,5-2H3)-L-leucine to determine the kinetics of HDL apoA-I. The lipid data in this study have been reported previously. Relative to placebo, 120 mg daily torcetrapib increased the amount of apoA-I in alpha1-migrating HDL in the atorvastatin (136%; P<0.001) and nonatorvastatin (153%; P<0.01) cohorts, whereas an increase of 382% (P<0.01) was observed in the 120 mg twice daily group. HDL apoA-I pool size increased by 8+/-15% in the atorvastatin cohort (P=0.16) and by 16+/-7% (P<0.0001) and 34+/-8% (P<0.0001) in the nonatorvastatin 120 mg QD and BID cohorts, respectively. These changes were attributable to reductions in HDL apoA-I fractional catabolic rate (FCR), with torcetrapib reducing HDL apoA-I FCR by 7% (P=0.10) in the atorvastatin cohort, by 8% (P<0.001) in the nonatorvastatin 120 mg QD cohort, and by 21% (P<0.01) in the nonatorvastatin 120 mg BID cohort. Torcetrapib did not affect HDL apoA-I production rate. In addition, torcetrapib did not significantly change serum markers of cholesterol or bile acid synthesis or fecal sterol excretion. CONCLUSIONS: These data indicate that partial inhibition of CETP via torcetrapib in patients with low HDL-C: (1) normalizes apoA-I levels within alpha1-migrating HDL, (2) increases plasma concentrations of HDL apoA-I by delaying apoA-I catabolism, and (3) does not significantly influence fecal sterol excretion.  (+info)

Management of dyslipidemia in women in the post-hormone therapy era. (8/1436)

OBJECTIVE: Cardiovascular disease (CVD) is the leading cause of death for women in the United States and is largely preventable. The American Heart Association has recently released evidence-based guidelines for the prevention of CVD in women; these include gender-specific recommendations for the management of dyslipidemia. This article reviews these recommendations and the evidence supporting them. DESIGN: This was a qualitative review of a systematic literature search related to lipid guidelines for women and discussion of rationale and evidence for new clinical recommendations. MAIN RESULTS: Lifestyle modifications are the cornerstone of lipid management. Substantial evidence from randomized clinical trials supports the use of low-density lipoprotein cholesterol-lowering therapy (primarily statins) in all high-risk women and the use of niacin or fibrates when high-density lipoprotein cholesterol is low or non-high-density lipoprotein cholesterol is elevated. Fewer data are available for women at lower or intermediate risk. CONCLUSIONS: Encouragement of lifestyle modification and appropriate use of lipid-altering therapy will have a substantial impact on reducing the burden of cardiovascular disease in women.  (+info)

Dyslipidemia is a condition characterized by an abnormal amount of cholesterol and/or triglycerides in the blood. It can be caused by genetic factors, lifestyle habits such as poor diet and lack of exercise, or other medical conditions such as diabetes or hypothyroidism.

There are several types of dyslipidemias, including:

1. Hypercholesterolemia: This is an excess of low-density lipoprotein (LDL) cholesterol, also known as "bad" cholesterol, in the blood. High levels of LDL cholesterol can lead to the formation of plaque in the arteries, increasing the risk of heart disease and stroke.
2. Hypertriglyceridemia: This is an excess of triglycerides, a type of fat found in the blood, which can also contribute to the development of plaque in the arteries.
3. Mixed dyslipidemia: This is a combination of high LDL cholesterol and high triglycerides.
4. Low high-density lipoprotein (HDL) cholesterol: HDL cholesterol, also known as "good" cholesterol, helps remove LDL cholesterol from the blood. Low levels of HDL cholesterol can increase the risk of heart disease and stroke.

Dyslipidemias often do not cause any symptoms but can be detected through a blood test that measures cholesterol and triglyceride levels. Treatment typically involves lifestyle changes such as eating a healthy diet, getting regular exercise, and quitting smoking. In some cases, medication may also be necessary to lower cholesterol or triglyceride levels.

Hyperlipidemias are a group of disorders characterized by an excess of lipids (fats) or lipoproteins in the blood. These include elevated levels of cholesterol, triglycerides, or both. Hyperlipidemias can be inherited (primary) or caused by other medical conditions (secondary). They are a significant risk factor for developing cardiovascular diseases, such as atherosclerosis and coronary artery disease.

There are two main types of lipids that are commonly measured in the blood: low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol, and high-density lipoprotein (HDL) cholesterol, known as "good" cholesterol. High levels of LDL cholesterol can lead to the formation of plaques in the arteries, which can narrow or block them and increase the risk of heart attack or stroke. On the other hand, high levels of HDL cholesterol are protective because they help remove LDL cholesterol from the bloodstream.

Triglycerides are another type of lipid that can be measured in the blood. Elevated triglyceride levels can also contribute to the development of cardiovascular disease, particularly when combined with high LDL cholesterol and low HDL cholesterol levels.

Hyperlipidemias are typically diagnosed through a blood test that measures the levels of various lipids and lipoproteins in the blood. Treatment may include lifestyle changes, such as following a healthy diet, getting regular exercise, losing weight, and quitting smoking, as well as medication to lower lipid levels if necessary.

Hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors, also known as statins, are a class of cholesterol-lowering medications. They work by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. By blocking this enzyme, the liver is stimulated to take up more low-density lipoprotein (LDL) cholesterol from the bloodstream, leading to a decrease in LDL cholesterol levels and a reduced risk of cardiovascular disease.

Examples of HMG-CoA reductase inhibitors include atorvastatin, simvastatin, pravastatin, rosuvastatin, and fluvastatin. These medications are commonly prescribed to individuals with high cholesterol levels, particularly those who are at risk for or have established cardiovascular disease.

It's important to note that while HMG-CoA reductase inhibitors can be effective in reducing LDL cholesterol levels and the risk of cardiovascular events, they should be used as part of a comprehensive approach to managing high cholesterol, which may also include lifestyle modifications such as dietary changes, exercise, and weight management.

Hypolipidemic agents are a class of medications that are used to lower the levels of lipids (fats) in the blood, particularly cholesterol and triglycerides. These drugs work by reducing the production or increasing the breakdown of fats in the body, which can help prevent or treat conditions such as hyperlipidemia (high levels of fats in the blood), atherosclerosis (hardening and narrowing of the arteries), and cardiovascular disease.

There are several different types of hypolipidemic agents, including:

1. Statins: These drugs block the action of an enzyme called HMG-CoA reductase, which is necessary for the production of cholesterol in the liver. By reducing the amount of cholesterol produced, statins can help lower LDL (bad) cholesterol levels and increase HDL (good) cholesterol levels.
2. Bile acid sequestrants: These drugs bind to bile acids in the intestines and prevent them from being reabsorbed into the bloodstream. This causes the liver to produce more bile acids, which requires it to use up more cholesterol, thereby lowering LDL cholesterol levels.
3. Nicotinic acid: Also known as niacin, this drug can help lower LDL and VLDL (very low-density lipoprotein) cholesterol levels and increase HDL cholesterol levels. It works by reducing the production of fatty acids in the liver.
4. Fibrates: These drugs are used to treat high triglyceride levels. They work by increasing the breakdown of fats in the body and reducing the production of VLDL cholesterol in the liver.
5. PCSK9 inhibitors: These drugs block the action of a protein called PCSK9, which helps regulate the amount of LDL cholesterol in the blood. By blocking PCSK9, these drugs can help lower LDL cholesterol levels.

It's important to note that hypolipidemic agents should only be used under the guidance and supervision of a healthcare provider, as they can have side effects and may interact with other medications.

Hypertriglyceridemia is a medical condition characterized by an elevated level of triglycerides in the blood. Triglycerides are a type of fat (lipid) found in your blood that can increase the risk of developing heart disease, especially when levels are very high.

In general, hypertriglyceridemia is defined as having triglyceride levels greater than 150 milligrams per deciliter (mg/dL) of blood. However, the specific definition of hypertriglyceridemia may vary depending on individual risk factors and medical history.

Hypertriglyceridemia can be caused by a variety of factors, including genetics, obesity, physical inactivity, excessive alcohol consumption, and certain medications. In some cases, it may also be a secondary consequence of other medical conditions such as diabetes or hypothyroidism. Treatment for hypertriglyceridemia typically involves lifestyle modifications such as dietary changes, increased exercise, and weight loss, as well as medication if necessary.

HDL (High-Density Lipoprotein) cholesterol is often referred to as "good" cholesterol. It is a type of lipoprotein that helps remove excess cholesterol from cells and carry it back to the liver, where it can be broken down and removed from the body. High levels of HDL cholesterol have been associated with a lower risk of heart disease and stroke.

Triglycerides are the most common type of fat in the body, and they're found in the food we eat. They're carried in the bloodstream to provide energy to the cells in our body. High levels of triglycerides in the blood can increase the risk of heart disease, especially in combination with other risk factors such as high LDL (bad) cholesterol, low HDL (good) cholesterol, and high blood pressure.

It's important to note that while triglycerides are a type of fat, they should not be confused with cholesterol, which is a waxy substance found in the cells of our body. Both triglycerides and cholesterol are important for maintaining good health, but high levels of either can increase the risk of heart disease.

Triglyceride levels are measured through a blood test called a lipid panel or lipid profile. A normal triglyceride level is less than 150 mg/dL. Borderline-high levels range from 150 to 199 mg/dL, high levels range from 200 to 499 mg/dL, and very high levels are 500 mg/dL or higher.

Elevated triglycerides can be caused by various factors such as obesity, physical inactivity, excessive alcohol consumption, smoking, and certain medical conditions like diabetes, hypothyroidism, and kidney disease. Medications such as beta-blockers, steroids, and diuretics can also raise triglyceride levels.

Lifestyle changes such as losing weight, exercising regularly, eating a healthy diet low in saturated and trans fats, avoiding excessive alcohol consumption, and quitting smoking can help lower triglyceride levels. In some cases, medication may be necessary to reduce triglycerides to recommended levels.

LDL, or low-density lipoprotein, is often referred to as "bad" cholesterol. It is one of the lipoproteins that helps carry cholesterol throughout your body. High levels of LDL cholesterol can lead to a buildup of cholesterol in your arteries, which can increase the risk of heart disease and stroke.

Cholesterol is a type of fat (lipid) that is found in the cells of your body. Your body needs some cholesterol to function properly, but having too much can lead to health problems. LDL cholesterol is one of the two main types of cholesterol; the other is high-density lipoprotein (HDL), or "good" cholesterol.

It's important to keep your LDL cholesterol levels in a healthy range to reduce your risk of developing heart disease and stroke. A healthcare professional can help you determine what your target LDL cholesterol level should be based on your individual health status and risk factors.

Cholesterol is a type of lipid (fat) molecule that is an essential component of cell membranes and is also used to make certain hormones and vitamins in the body. It is produced by the liver and is also obtained from animal-derived foods such as meat, dairy products, and eggs.

Cholesterol does not mix with blood, so it is transported through the bloodstream by lipoproteins, which are particles made up of both lipids and proteins. There are two main types of lipoproteins that carry cholesterol: low-density lipoproteins (LDL), also known as "bad" cholesterol, and high-density lipoproteins (HDL), also known as "good" cholesterol.

High levels of LDL cholesterol in the blood can lead to a buildup of cholesterol in the walls of the arteries, increasing the risk of heart disease and stroke. On the other hand, high levels of HDL cholesterol are associated with a lower risk of these conditions because HDL helps remove LDL cholesterol from the bloodstream and transport it back to the liver for disposal.

It is important to maintain healthy levels of cholesterol through a balanced diet, regular exercise, and sometimes medication if necessary. Regular screening is also recommended to monitor cholesterol levels and prevent health complications.

Cardiovascular diseases (CVDs) are a class of diseases that affect the heart and blood vessels. They are the leading cause of death globally, according to the World Health Organization (WHO). The term "cardiovascular disease" refers to a group of conditions that include:

1. Coronary artery disease (CAD): This is the most common type of heart disease and occurs when the arteries that supply blood to the heart become narrowed or blocked due to the buildup of cholesterol, fat, and other substances in the walls of the arteries. This can lead to chest pain, shortness of breath, or a heart attack.
2. Heart failure: This occurs when the heart is unable to pump blood efficiently to meet the body's needs. It can be caused by various conditions, including coronary artery disease, high blood pressure, and cardiomyopathy.
3. Stroke: A stroke occurs when the blood supply to a part of the brain is interrupted or reduced, often due to a clot or a ruptured blood vessel. This can cause brain damage or death.
4. Peripheral artery disease (PAD): This occurs when the arteries that supply blood to the limbs become narrowed or blocked, leading to pain, numbness, or weakness in the legs or arms.
5. Rheumatic heart disease: This is a complication of untreated strep throat and can cause damage to the heart valves, leading to heart failure or other complications.
6. Congenital heart defects: These are structural problems with the heart that are present at birth. They can range from mild to severe and may require medical intervention.
7. Cardiomyopathy: This is a disease of the heart muscle that makes it harder for the heart to pump blood efficiently. It can be caused by various factors, including genetics, infections, and certain medications.
8. Heart arrhythmias: These are abnormal heart rhythms that can cause the heart to beat too fast, too slow, or irregularly. They can lead to symptoms such as palpitations, dizziness, or fainting.
9. Valvular heart disease: This occurs when one or more of the heart valves become damaged or diseased, leading to problems with blood flow through the heart.
10. Aortic aneurysm and dissection: These are conditions that affect the aorta, the largest artery in the body. An aneurysm is a bulge in the aorta, while a dissection is a tear in the inner layer of the aorta. Both can be life-threatening if not treated promptly.

It's important to note that many of these conditions can be managed or treated with medical interventions such as medications, surgery, or lifestyle changes. If you have any concerns about your heart health, it's important to speak with a healthcare provider.

Lipids are a broad group of organic compounds that are insoluble in water but soluble in nonpolar organic solvents. They include fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E, and K), monoglycerides, diglycerides, triglycerides, and phospholipids. Lipids serve many important functions in the body, including energy storage, acting as structural components of cell membranes, and serving as signaling molecules. High levels of certain lipids, particularly cholesterol and triglycerides, in the blood are associated with an increased risk of cardiovascular disease.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

'Alcohol drinking' refers to the consumption of alcoholic beverages, which contain ethanol (ethyl alcohol) as the active ingredient. Ethanol is a central nervous system depressant that can cause euphoria, disinhibition, and sedation when consumed in small to moderate amounts. However, excessive drinking can lead to alcohol intoxication, with symptoms ranging from slurred speech and impaired coordination to coma and death.

Alcohol is metabolized in the liver by enzymes such as alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). The breakdown of ethanol produces acetaldehyde, a toxic compound that can cause damage to various organs in the body. Chronic alcohol drinking can lead to a range of health problems, including liver disease, pancreatitis, cardiovascular disease, neurological disorders, and increased risk of cancer.

Moderate drinking is generally defined as up to one drink per day for women and up to two drinks per day for men, where a standard drink contains about 14 grams (0.6 ounces) of pure alcohol. However, it's important to note that there are no safe levels of alcohol consumption, and any level of drinking carries some risk to health.

Beer is a fermented alcoholic beverage typically made from malted barley, hops, water, and yeast. The brewing process involves steeping the malt in water to create a sugary solution called wort, which is then boiled with hops for flavor and preservation. After cooling, the wort is fermented with yeast, which converts the sugar into alcohol and carbon dioxide. There are many varieties of beer, including ales, lagers, stouts, and porters, that differ in their ingredients, brewing methods, and flavor profiles. The alcohol content of beer generally ranges from 3% to 12% ABV (alcohol by volume).

Alcoholic beverages are drinks that contain ethanol (ethyl alcohol), which is produced by the fermentation of yeast, sugars, and starches. The amount of alcohol in a drink is measured in terms of "alcohol content" or "alcohol by volume" (ABV). Different types of alcoholic beverages include:

1. Beer: A fermented beverage made from grains, such as barley, wheat, or rye. The alcohol content of beer typically ranges from 3-6% ABV.
2. Wine: A fermented beverage made from grapes or other fruits. The alcohol content of wine usually falls between 10-15% ABV.
3. Spirits (or liquors): Distilled beverages with higher alcohol content, typically ranging from 40-50% ABV. Examples include vodka, whiskey, rum, gin, and tequila.
4. Fortified wines: Wines that have had a distilled spirit added to them, increasing their alcohol content. Examples include port, sherry, and madeira, which typically contain 17-20% ABV.
5. Malt beverages: Fermented beverages made from malted barley or other grains, with additional flavorings or sweeteners. These can range in alcohol content from around 4-8% ABV.

It is important to note that excessive consumption of alcoholic beverages can lead to various health issues, including addiction, liver disease, and an increased risk of accidents and injuries. Moderate drinking is generally defined as up to one drink per day for women and up to two drinks per day for men, although individual tolerance and sensitivity to alcohol may vary.

'Wine' is not typically defined in medical terms, but it is an alcoholic beverage made from the fermentation of grape juice. It contains ethanol and can have varying levels of other compounds depending on the type of grape used, the region where it was produced, and the method of fermentation.

In a medical context, wine might be referred to in terms of its potential health effects, which can vary. Moderate consumption of wine, particularly red wine, has been associated with certain health benefits, such as improved cardiovascular health. However, heavy or excessive drinking can lead to numerous health problems, including addiction, liver disease, heart disease, and an increased risk of various types of cancer.

It's important to note that while moderate consumption may have some health benefits, the potential risks of alcohol consumption generally outweigh the benefits for many people. Therefore, it's recommended that individuals who do not currently drink alcohol should not start drinking for health benefits. Those who choose to drink should do so in moderation, defined as up to one drink per day for women and up to two drinks per day for men.

Ethanol is the medical term for pure alcohol, which is a colorless, clear, volatile, flammable liquid with a characteristic odor and burning taste. It is the type of alcohol that is found in alcoholic beverages and is produced by the fermentation of sugars by yeasts.

In the medical field, ethanol is used as an antiseptic and disinfectant, and it is also used as a solvent for various medicinal preparations. It has central nervous system depressant properties and is sometimes used as a sedative or to induce sleep. However, excessive consumption of ethanol can lead to alcohol intoxication, which can cause a range of negative health effects, including impaired judgment, coordination, and memory, as well as an increased risk of accidents, injuries, and chronic diseases such as liver disease and addiction.

Alcoholism is a chronic and often relapsing brain disorder characterized by the excessive and compulsive consumption of alcohol despite negative consequences to one's health, relationships, and daily life. It is also commonly referred to as alcohol use disorder (AUD) or alcohol dependence.

The diagnostic criteria for AUD include a pattern of alcohol use that includes problems controlling intake, continued use despite problems resulting from drinking, development of a tolerance, drinking that leads to risky behaviors or situations, and withdrawal symptoms when not drinking.

Alcoholism can cause a wide range of physical and psychological health problems, including liver disease, heart disease, neurological damage, mental health disorders, and increased risk of accidents and injuries. Treatment for alcoholism typically involves a combination of behavioral therapies, medications, and support groups to help individuals achieve and maintain sobriety.

Those with primary dyslipidemias are at higher risk of getting complications of dyslipidemias, such as atherosclerotic ... Dyslipidemia is a metabolic disorder characterized by abnormally high or low amounts of any or all lipids (e.g. fats, ... Although dyslipidemia is a risk factor for ASCVD, abnormal levels don't mean that lipid lowering agents need to be started. ... Dyslipidemias can also be classified based on the underlying cause, whether it is primary, secondary, or a combination of both ...
Durrington P (2003). "Dyslipidaemia". Lancet. 362 (9385): 717-31. doi:10.1016/S0140-6736(03)14234-1. PMID 12957096. (Articles ...
Durrington P (August 2003). "Dyslipidaemia". Lancet. 362 (9385): 717-731. doi:10.1016/S0140-6736(03)14234-1. PMID 12957096. ...
Durrington P (2003). "Dyslipidaemia". Lancet. 362 (9385): 717-31. doi:10.1016/S0140-6736(03)14234-1. PMID 12957096. Buchwald H ...
FH is classified as a type 2 familial dyslipidemia. There are five types of familial dyslipidemia (not including subtypes), and ... Durrington P (2003). "Dyslipidaemia". Lancet. 362 (9385): 717-31. doi:10.1016/S0140-6736(03)14234-1. PMID 12957096. S2CID ...
Kopin L, Lowenstein C (December 2017). "Dyslipidemia". Annals of Internal Medicine. 167 (11): ITC81-ITC96. doi:10.7326/ ... Hyperlipidemia represents a subset of dyslipidemia and a superset of hypercholesterolemia. Hyperlipidemia is usually chronic ... "Final Update Summary: Lipid Disorders in Adults (Cholesterol, Dyslipidemia): Screening". US Preventive Services Task Force. ...
Chou Roger (9 August 2016). "Screening for Dyslipidemia in Younger Adults: A Systematic Review for the U.S. Preventive Services ... Genest, J; Frohlich, J; Fodor, G; McPherson, R (2003-10-28). "Recommendations for the management of dyslipidemia and the ... Durrington, P (August 2003). "Dyslipidaemia". The Lancet. 362 (9385): 717-31. doi:10.1016/S0140-6736(03)14234-1. PMID 12957096 ... and dyslipidemia (any abnormalities of lipid and lipoprotein levels in the blood). Elevated levels of non-HDL cholesterol and ...
Finally, dyslipidemia affects the vast majority (up to 97%) of individuals with diabetes and contributes to their elevated risk ... Diabetic dyslipidemia. Diabetes & Cardiovascular Disease Review. 2006;3:1-4. Schubert CM et al. Predictive ability of childhood ... Of the components of the cardiometabolic syndrome, only the prevalence of dyslipidemia has declined in the United States. ...
Wu L, Parhofer KG (December 2014). "Diabetic dyslipidemia". Metabolism. 63 (12): 1469-79. doi:10.1016/j.metabol.2014.08.010. ...
Ramasamy I (February 2016). "Update on the molecular biology of dyslipidemias". Clinica Chimica Acta; International Journal of ... Pisaniello AD, Scherer DJ, Kataoka Y, Nicholls SJ (February 2015). "Ongoing challenges for pharmacotherapy for dyslipidemia". ...
Dyslipidemia and hypertension are well known to contribute to endothelial dysfunction, and lowering blood pressure and LDL has ... Le Master, Elizabeth; Levitan, Irena (2019-01-22). "Endothelial stiffening in dyslipidemia". Aging. 11 (2): 299-300. doi: ...
"Agents Used in Dyslipidemia , Basic & Clinical Pharmacology, 15e , AccessPharmacy , McGraw-Hill Medical". accesspharmacy. ...
Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M (2010). "Pathophysiology of dyslipidemia in ...
"Prediction of genetic risk for dyslipidemia". Genomics. 90 (5): 551-8. doi:10.1016/j.ygeno.2007.08.001. PMID 17919884. Kursula ...
"Targeting Mixed Dyslipidemia and Metabolic Syndrome". Metabolex, Inc. 2005. Archived from the original on 2006-10-17. Bowlus CL ... Billin AN (October 2008). "PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a ... According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 ...
A study in genetic variants that regulate lipid metabolism and determine the susceptibility to dyslipidemia in Japanese ... "Association of genetic variants with dyslipidemia". Molecular Medicine Reports. 12 (4): 5429-36. doi:10.3892/mmr.2015.4081. ...
Pearson, Thomas A. (2010). "5. Clinical trial evidence for treatment of dyslipidaemia in the prevention of cardiovascular ... disease". In Kwiterovich, Peter O. (ed.). The Johns Hopkins Textbook of Dyslipidemia. Philadelphia: Lippincott Williams & ...
The diseases that were targeted were hypertension and obesity dyslipidemias. Dietary habits, exercise, and alcohol consumption ...
El Harchaoui K, van der Steeg WA, Stroes ES, Kastelein JJ (August 2007). "The role of CETP inhibition in dyslipidemia". Current ...
Kim KA, Park HJ (January 2023). "New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)". Journal of ... Boden WE, Sidhu MS, Toth PP (2014). "The therapeutic role of niacin in dyslipidemia management". J. Cardiovasc. Pharmacol. Ther ...
Dyslipidemia Feingold, Kenneth R. (2000), Feingold, Kenneth R.; Anawalt, Bradley; Boyce, Alison; Chrousos, George (eds.), " ...
... is considered a type IV familial dyslipidemia it is distinguished from other dyslipidemias based ... Familial hypertriglyceridemia (type IV familial dyslipidemia) is a genetic disorder characterized by the liver overproducing ... Familial hypertriglyceridemia separates itself from other dyslipidemias with significantly high triglycerides and low HDL ... The phenotypes include types I, IIa, IIb, III, IV, and V dyslipidemias. ...
Benatar JR, Stewart RA (2007). "Is it time to stop treating dyslipidaemia with fibrates?". The New Zealand Medical Journal. 120 ... "Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia". Annals of Internal ... "Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia". The American Journal of Clinical ...
Dyslipidemia (or dyslipidaemia) Abnormal lipid levels in the blood. Includes levels that are too high (triglycerides, LDLs) and ... levels that are too low (HDLs). People with insulin resistance and diabetes often have dyslipidemia. Although the cause-and- ...
2022). Lipids: Update on Diagnosis and Management of Dyslipidemia. Elsevier. ISBN 978-0-323-98695-3. "Connie Newman". American ...
McKenney JM (May 2005). "Efficacy and safety of rosuvastatin in treatment of dyslipidemia". American Journal of Health-System ... The primary uses of atorvastatin is for the treatment of dyslipidemia and the prevention of cardiovascular disease: ... Statins (predominantly simvastatin) have been trialled in combination with fibrates to manage dyslipidemia in patients who also ... in the treatment of diabetic dyslipidemia". The Journal of Clinical Endocrinology and Metabolism. 88 (7): 3212-3217. doi: ...
December 2008). "Common variants at 30 loci contribute to polygenic dyslipidemia". Nat. Genet. 41 (1): 56-65. doi:10.1038/ng. ...
General ApolloLipids - Provides dyslipidemia and cardiovascular disease prevention and treatment information as well as ... Bełtowski J (2008). "Liver X receptors (LXR) as therapeutic targets in dyslipidemia". Cardiovascular Therapeutics. 26 (4): 297- ... education organization for health care professionals who seek to prevent morbidity and mortality stemming from dyslipidemias ...
January 2009). "Common variants at 30 loci contribute to polygenic dyslipidemia". Nature Genetics. 41 (1): 56-65. doi:10.1038/ ...
Rau O, Zettl H, Popescu L, Steinhilber D, Schubert-Zsilavecz M (February 2008). "The treatment of dyslipidemia--what's left in ... Later research discredited the concept of ACAT inhibition as a treatment for dyslipidemia and atherosclerosis, and interest in ...
Those with primary dyslipidemias are at higher risk of getting complications of dyslipidemias, such as atherosclerotic ... Dyslipidemia is a metabolic disorder characterized by abnormally high or low amounts of any or all lipids (e.g. fats, ... Although dyslipidemia is a risk factor for ASCVD, abnormal levels dont mean that lipid lowering agents need to be started. ... Dyslipidemias can also be classified based on the underlying cause, whether it is primary, secondary, or a combination of both ...
Purpose. The efficacy and safety of phytosterols for the management of dyslipidemia are reviewed.. Summary. Phytosterols have ... This article reviews the efficacy and safety of phytosterols in the management of dyslipidemia. ...
Search hundreds of CME and MOC activities-free or discounted for ACP members-by topic, format, and state CME requirements to find education that matches your needs.. Browse Activities. ...
Dyslipidemia in pediatricians practice Rev Cardiovasc Med. 2021 Sep 24;22(3):817-834. doi: 10.31083/j.rcm2203088. ... Since risk factors can be identified at the preclinical stage of the atherosclerotic process, dyslipidemia phenotyping will ... Disorders of lipid metabolism - dyslipidemias are attributed to the most significant risk factor for atherosclerotic ...
... related dyslipidemia. Some 50-70% of patients receiving combination antiretroviral therapy (ART) involving PIs develop lipid ... Strategies for management and treatment of dyslipidemia in HIV/AIDS AIDS Care. 2006 Feb;18(2):149-57. doi: 10.1080/ ... Treatment of HIV dyslipidemia should include lifestyle modifications such as a low-fat diet, increased exercise, reduced ... related dyslipidemia. Some 50-70% of patients receiving combination antiretroviral therapy (ART) involving PIs develop lipid ...
Your access to the latest cardiovascular news, science, tools and resources.
... for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults ... Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. Technology appraisal guidance [TA733]. Published ... Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in ...
Dyslipidemia and Prevention of Cardiovascular Disease /getattachment/fc96caab-3ec5-4cc7-8080-3268e09546ee/Dyslipidemia-and- ... Dyslipidemia and Prevention of Cardiovascular Disease back to all guideline summaries Add to Bookmarks Add to Bookmarks 2959 ... Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and ...
The global market for drugs to treat dyslipidemia will grow by an average of around 2% a year from 2012 to 2022, by which time ... The global market for drugs to treat dyslipidemia will grow by an average of around 2% a year from 2012 to 2022, by which time ... the pendulum appears to be swinging back to LDL-C as the most robust modifiable dyslipidemia target, according to experts we ... for ezetimibe is the most highly-anticipated near-term event in the dyslipidemia market, the report adds. ...
Rutin potentially attenuates fluoride induced oxidative stress mediated cardiotoxicity, blood toxicity and dyslipidemia in rats ... Epigallocatechin gallate potentially attenuates fluoride induced oxidative stress mediated cardiotoxicity and dyslipidemia in ... that treatment with EGCG prior to F intoxication has a significant role in protecting F-induced cardiotoxicity and dyslipidemia ...
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you dont have an account you can just enter your email address in the email box below ...
In this review we analyzed the mechanisms that relate NAFLD with metabolic syndrome and dyslipidemia and its association with ... 4. Fatty Liver, Dyslipidemia and the Metabolic Syndrome. The presence of dyslipidemia (hypercholesterolemia, ... This article belongs to the Special Issue Dyslipidemia and Obesity). Download keyboard_arrow_down Download PDF Download PDF ... non-alcoholic fatty liver(NAFLD); steatosis; visceral fat; lipotoxicity; insulin resistance; free fatty acids; dyslipidemia; ...
News stories and articles referencing Dyslipidemia on European Pharmaceutical Review ... Dyslipidemia treatment market value will approach $38 billion by 2023. 20 May 2015 , By Victoria White ... The global treatment market for dyslipidemia will more than double from $15.4 billion in 2013 to an estimated $37.9 billion by ...
Ronald Krauss on LDL Cholesterol, Particle Size, Heart Disease & Atherogenic Dyslipidemia FoundMyFitness * * Medicine ...
Dyslipidemia is a common condition coexisting with type 2 diabetes and a clear risk factor for the development of ... Fast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape - Apr 21, 2023. ... atherosclerotic cardiovascular disease (ASCVD). The combination of hyperglycemia and dyslipidemia produces an enhanced ...
... ... the potential of obicetrapib plus ezetimibe as an adjunct to statin therapy for improving management of dyslipidemia. ...
Whats the evidence for LDL and other non-HDL targets for primary and secondary prevention of heart disease? What are the comparative benefits versus toxicities of all lipid-lowering medications in clinical use? Addressing these and other questions from the standpoing of recent NLA recommendations is Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL. Produced in partnership with
Discuss recent updates on dyslipidemia in pediatric CKD. *Describe the relationship between adiposity, dyslipidemia, and ... Vascular Effects of Dyslipidemia in Children and Adolescents. 10:30 AM - 11:00 AM. *Sarah de Ferranti, MD, MPH ... Dyslipidemia in Pediatric CKD: Risk for Stiff Vessels?. November 04, 2023 , 10:30 AM - 12:30 PM. Location: Room 108, ... Adiposity, Dyslipidemia, and Cardiovascular Risk in CKD. 11:30 AM - 12:00 PM. *Ian Macumber, MD, MS ...
Dysregulation of hepatic and lipoprotein metabolism in the atherogenic dyslipidemia. This content is available to Members & ...
Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. ... 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease ... 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease ... Cite this document as follows: Clinical Resource, Canadian Dyslipidemia Recommendations. Pharmacists Letter/Pharmacy ...
Background Statins are first choice for treatment of dyslipidaemia in both secondary and primary cardiovascular disease ... Dyslipidaemia and atherosclerotic vascular disease: DYSIS results in the UK. December 2013Br J Cardiol 2013;20(suppl 3):S1-S19 ... Other aspects of dyslipidaemia, including low HDL-C and elevated triglycerides, may also require a therapeutic strategy beyond ... Results from the DYSlipidaemia International Study (DYSIS) in 22,063 statin-treated patients across 11 European countries and ...
However, Canada recently released the third iteration of its guideline for the Diagnosis and Treatment of Dyslipidemia and ... Northern Light: A Commentary on the 2009 Canadian Guidelines for the Diagnosis and Treatment of Dyslipidemia and Prevention of ... However, Canada recently released the third iteration of its guideline for the Diagnosis and Treatment of Dyslipidemia and ... Commentary on the 2009 Canadian Guidelines for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular ...
In the present study, we investigate whether co-treatment with betahistine is able to prevent dyslipidemia induced by chronic ... dyslipidemia and other metabolic disorders. Both animal and clinical studies have shown that co-treatment with betahistine (a ... hepatic H1 receptors via modulation of AMPKα-SREBP-1 and PPARα-dependent pathways to ameliorate olanzapine-induced dyslipidemia ... In the present study, we investigate whether co-treatment with betahistine is able to prevent dyslipidemia induced by chronic ...
Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada)-dedicated to using leading-edge science to save and improve lives around the world. Learn more about the MSD Manuals and our commitment to Global Medical Knowledge.. ...
Germ-Free Swiss Webster Mice on a High-Fat Diet Develop Obesity, Hyperglycemia, and Dyslipidemia. ... Germ-Free Swiss Webster Mice on a High-Fat Diet Develop Obesity, Hyperglycemia, and Dyslipidemia.. ...
GNS-214-C in Dyslipidemia Drug Details:. GNS-214-C is under development for the treatment of dyslipidemia. It is an ... Access a live Likelihood of Approval and Phase Transition Success Rate Model - GNS-214-C in Dyslipidemia dashboard for 12 ... Likelihood of Approval and Phase Transition Success Rate Model - GNS-214-C in Dyslipidemia. Powered by ... GNS-214-C in Dyslipidemia in real time. ...
The National Strategy And Plan Of Action Against Diabetes, Hypertension, Dyslipidemia And Obesity in Jordan. Country(ies): ... The National Strategy And Plan Of Action Against Diabetes, Hypertension, Dyslipidemia And Obesity in Jordan ...
This Clinical Perspective provides an update with a focus on nutrition interventions for the three most common dyslipidemias in ... Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association. J Clin ... The National Lipid Association previously published recommendations for lifestyle therapies to manage dyslipidemia. ... combined dyslipidemia, with elevations in both LDL-C and TG levels. Lowering LDL-C and non-high-density lipoprotein cholesterol ...
  • The study aimed at describing 2AG associations with visceral obesity, dyslipidaemia, insulin resistance and hypertension in females according to BMI and menopausal status. (endocrine-abstracts.org)
  • Although statistically not-significant, the trend for cardio- metabolic and behavioral risk factors (hypertension, diabetes mellitus, dyslipidemia, smoking, alcohol and khat use) was higher in the group diagnosed with HAND. (who.int)
  • Dyslipidemia is a metabolic disorder characterized by abnormally high or low amounts of any or all lipids (e.g. fats, triglycerides, cholesterol, phospholipids) or lipoproteins in the blood. (wikipedia.org)
  • The three main blood levels collected to assess for dyslipidemia is triglycerides (TG), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C). High triglyceride levels (>1.7 mmol/L fasting) can indicate dyslipidemia. (wikipedia.org)
  • Dyslipidemia , on the other hand, is an elevated level of cholesterol or triglycerides in the bloodstream. (familycarers.org.uk)
  • Dyslipidemia is a condition characterized by the presence of abnormal levels of blood lipids, such as cholesterol and triglycerides. (salusfy.com)
  • Generally, the doctor through common blood tests, in which parameters such as good and bad cholesterol levels, triglycerides, as well as also fat and sugar levels are measured, is able to give an opinion on the possible occurrence of dyslipidemia, and by also analyzing our lifestyle to see if we follow a varied, balanced diet and lead a healthy lifestyle is able to help us prevent this disease. (salusfy.com)
  • The term dyslipidaemia identifies an elevated level of lipids (cholesterol, triglycerides or both) carried in the blood by lipoproteins. (purplesuite.app)
  • Another blood level collected to assess dyslipidemia is HDL-C. HDL cholesterol is made up of very little lipids and a high amount of protein. (wikipedia.org)
  • Some diseases that are associated with a higher risk of dyslipidemia are uncontrolled diabetes mellitus, cholestatic liver disease, chronic kidney disease, hypothyroidism, and polycystic ovarian syndrome. (wikipedia.org)
  • Each clinician must decide, with their patients, the best approach for managing dyslipidaemia in diabetes. (who.int)
  • Dyslipidemia is a common condition coexisting with type 2 diabetes and a clear risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). (medscape.com)
  • Linking diabetes and dyslipidemia increase the risk of developing multiple chronic conditions, including heart disease, stroke, and more. (familycarers.org.uk)
  • If you've been prescribed medications for diabetes or dyslipidemia, managing the two simultaneously is key for keeping yourself healthy and protecting your heart. (familycarers.org.uk)
  • What is Diabetes & Dyslipidemia? (familycarers.org.uk)
  • Managing diabetes and dyslipidemia involves both medication side effects and lifestyle changes. (familycarers.org.uk)
  • Eat healthy - Eating a balanced diet with plenty of fresh fruits, vegetables, whole grains, and lean proteins is essential for managing diabetes and dyslipidemia. (familycarers.org.uk)
  • The key to managing diabetes and dyslipidemia is to be proactive with your healthcare. (familycarers.org.uk)
  • Regular doctor visits and following up on your medications are what keep your diabetes and dyslipidemia in check and maintain your overall health and wellbeing. (familycarers.org.uk)
  • Diagnosing and properly managing diabetes and dyslipidemia is essential to your overall health and wellbeing. (familycarers.org.uk)
  • Taking medications as prescribed, eating a healthy diet, and being physically active are all integral parts of keeping your diabetes and dyslipidemia under control and benefiting from linked health conditions and health. (familycarers.org.uk)
  • Germ-Free Swiss Webster Mice on a High-Fat Diet Develop Obesity, Hyperglycemia, and Dyslipidemia. (oregonstate.edu)
  • Mexico ranks second in the global prevalence of obesity in the adult population , which increases the probability of developing dyslipidemia . (bvsalud.org)
  • The study aimed to estimate the prevalence of obesity, high blood pressure (HBP) and dyslipidemia and its associated factors. (bvsalud.org)
  • Secondary causes contribute to many cases of dyslipidemia in adults. (msdmanuals.com)
  • In fact, Treatment of nonsevere cases of dyslipidemia mainly involves adopting a proper diet, low in saturated fat and rich in fruits, vegetables, whole grains, and lean proteins, as well as it is also important to limit the consumption of alcohol and simple sugars, such as those found in carbonated soft drinks and sweets. (salusfy.com)
  • The global treatment market for dyslipidemia will more than double from $15.4 billion in 2013 to an estimated $37.9 billion by 2023, according to GlobalData. (europeanpharmaceuticalreview.com)
  • Data from the phase 2 ROSE2 study presented at the National Lipid Association (NLA) Scientific Sessions 2023 is highlighting the potential of obicetrapib plus ezetimibe as an adjunct to statin therapy for improving management of dyslipidemia . (consultantlive.com)
  • Since risk factors can be identified at the preclinical stage of the atherosclerotic process, dyslipidemia phenotyping will facilitate identifying children and adolescents at risk of developing cardiovascular pathologies in the future. (nih.gov)
  • Due to the positive functions of HDL cholesterol, a low level indicates dyslipidemia and is a risk factor for complications. (wikipedia.org)
  • If your cholesterol is abnormally high, your doctor may suggest additional blood tests to accurately diagnose dyslipidemia. (familycarers.org.uk)
  • Second-generation antipsychotics including olanzapine are associated with weight gain, dyslipidemia and other metabolic disorders. (edu.au)
  • Conclusions: Plasma 2AG is a valuable biomarker of clustering insulin resistance and dyslipidemia in lean menopausal women, and may play a causative role in menopause-related metabolic worsening. (endocrine-abstracts.org)
  • Some common genetic disorders associated with primary dyslipidemias are homozygous or heterozygous hypercholesterolemia, familial hypertriglyceridemia, combined hyperlipidemia, and HDL-C metabolism disorders. (wikipedia.org)
  • However, Canada recently released the third iteration of its guideline for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease. (aacc.org)
  • Subjects eligible for the treatment of dyslipidemia with statins according the current guidelines NCEP ATPIII and IV Brazilian Guidelines of Dyslipidemia and Atherosclerosis Prevention. (astrazenecaclinicaltrials.com)
  • Disorders of blood lipid metabolism are an established risk factor for atherosclerosis, therefore the importance of therapeutic regulation of dyslipidaemia for the prevention of cardio- and cerebrovascular complications is recognized by professional societies worldwide. (gl-pharma.com)
  • management of dyslipidaemia for prevention of vascular complications. (gl-pharma.com)
  • Therefore, developing tools that facilitate the prediction of dyslipidemias is essential for prevention and early treatment . (bvsalud.org)
  • The findings of this study shed light on significant factors that play a role in dyslipidemia development, aiding in the early identification, prevention, and treatment of this condition. (bvsalud.org)
  • Dyslipidemia is a risk factor for the development of atherosclerotic cardiovascular diseases (ASCVD), which include coronary artery disease, cerebrovascular disease, and peripheral artery disease. (wikipedia.org)
  • Disorders of lipid metabolism - dyslipidemias are attributed to the most significant risk factor for atherosclerotic cardiovascular diseases. (nih.gov)
  • Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults. (nice.org.uk)
  • Primary dyslipidemias are caused by genetic disorders that can cause abnormal lipid levels without any other obvious risk factors. (wikipedia.org)
  • [ 2 ] The purpose of this article is to discuss the basic biology of lipoproteins, the pathophysiology of dyslipidemias, the interpretation of lipid levels in pediatric patients, dyslipidemia screening, and the management of pediatric lipid abnormalities. (medscape.com)
  • The "Dyslipidemia Market Analysis, 2020" research report provides a detailed analysis of the ongoing market trends, opportunities, growth areas, drivers, and challenges, which would enable stakeholders to align their market strategies according to the present & future market dynamics. (articlemela.com)
  • The combination of hyperglycemia and dyslipidemia produces an enhanced environment within the circulation, which may accelerate the progression to atherosclerosis. (medscape.com)
  • Other factors, such as comorbid conditions and lifestyle in addition to dyslipidemia, is considered in a cardiovascular risk assessment. (wikipedia.org)
  • In contrast to primary dyslipidemias, secondary dyslipidemas are based on modifiable environmental or lifestyle factors. (wikipedia.org)
  • Yet we see continued physician optimism for CETP inhibitors, which also primarily target HDL-C. While this enthusiasm is driven by their additional LDL-C-lowering ability, the pendulum appears to be swinging back to LDL-C as the most robust modifiable dyslipidemia target, according to experts we interviewed," says Dr Narang. (pharmatimes.com)
  • Those with primary dyslipidemias are at higher risk of getting complications of dyslipidemias, such as atherosclerotic cardiovascular disease, at a younger age. (wikipedia.org)
  • Deep dive into 2019 ESC-EAS dyslipidaemia target. (escardio.org)
  • The global market for drugs to treat dyslipidemia will grow by an average of around 2% a year from 2012 to 2022, by which time it will be worth just over $31 billion, according to new research. (pharmatimes.com)
  • Thus, results of the present study clearly demonstrated that treatment with EGCG prior to F intoxication has a significant role in protecting F-induced cardiotoxicity and dyslipidemia in rats. (fluoridealert.org)
  • This study provided the first evidence that betahistine could act on hepatic H1 receptors via modulation of AMPKα-SREBP-1 and PPARα-dependent pathways to ameliorate olanzapine-induced dyslipidemia in rats. (edu.au)
  • Both primary and secondary causes contribute to dyslipidemias in varying degrees. (msdmanuals.com)
  • More than 60% of type 2 diabetic subjects in the Eastern Mediterranean Region have some degree of dyslipidaemia. (who.int)
  • With the improved survival of HIV-infected patients, there are increased concerns about the long-term effects of treatment, including protease inhibitor (PI)-related dyslipidemia. (nih.gov)
  • Treatment of HIV dyslipidemia should include lifestyle modifications such as a low-fat diet, increased exercise, reduced alcohol consumption and smoking cessation. (nih.gov)
  • Betahistine co-treatment ameliorates dyslipidemia induced by chronic o" by Xuemei Liu, Jiamei Lian et al. (edu.au)
  • In the present study, we investigate whether co-treatment with betahistine is able to prevent dyslipidemia induced by chronic olanzapine treatment and the underlying mechanisms. (edu.au)
  • GNS-214-C is under development for the treatment of dyslipidemia. (globaldata.com)
  • A unique sign of primary dyslipidemias is that patients will often present with acute pancreatitis or xanthomas on the skin, eyelids or around the cornea. (wikipedia.org)
  • Dezima Pharma has announced the publication of the phase 2b TULIP study results with its CETP inhibitor, TA-8995, in patients with mild dyslipidaemia. (europeanpharmaceuticalreview.com)
  • Prolonged elevation of insulin resistance can also lead to dyslipidemia. (wikipedia.org)
  • The efficacy and safety of phytosterols for the management of dyslipidemia are reviewed. (medscape.com)
  • This article reviews the efficacy and safety of phytosterols in the management of dyslipidemia. (medscape.com)
  • The session discusses recent updates, additive risk of dyslipidemia in children with CKD, and existing controversies in management of dyslipidemia in children with CKD. (asn-online.org)
  • Flowers, E & Aouizerat, BE 2013, ' MicroRNA associated with dyslipidemia and coronary disease in humans ', Physiological Genomics , vol. 45, no. 24, pp. 1199-1205. (nyu.edu)
  • Session] Dyslipidemia in Pediatric CKD: Risk for Stiff Vessels? (asn-online.org)
  • Dyslipidemia in Pediatric CKD: Risk for Stiff Vessels? (asn-online.org)
  • Although dyslipidemia is a risk factor for ASCVD, abnormal levels don't mean that lipid lowering agents need to be started. (wikipedia.org)
  • Dyslipidemias can also be classified based on the underlying cause, whether it is primary, secondary, or a combination of both. (wikipedia.org)
  • Product details Primary Care and Dyslipidemia: What Should You Do? (francefoundation.com)
  • Our primary objective was to identify potential factors associated with different types of dyslipidemia in both men and women . (bvsalud.org)
  • How Well Can We Control Dyslipidemias Through Lifestyle Modifications? (unina.it)
  • The role for lifestyle modifications to correct dyslipidemia(s) is reviewed. (unina.it)
  • In this study, we utilized a dataset from a Mexico City cohort consisting of 2,621 participants, men and women aged between 20 and 50 years, with and without some type of dyslipidemia . (bvsalud.org)